4D pharma will present preclinical data on its asthma programme at the Keystone Symposium: Microbiome in Health and Disease meeting from February 5 - 9 in Keystone, Colorado. The company will present a poster on its lead candidate, MRx0004, a single-strain live biotherapeutic under investigation for the treatment of asthma which is set to hit the clinic in 2018.
The data presented are:
Immunomodulatory effects of a commensal gut microbe alleviate inflammatory responses in an animal model of severe asthma through reduction of neutrophil infiltration in the lung, presented by Phillip Cowie, PhD, 4D Pharma Research.
